In summary, the findings of this study indicate that LDL and ApoA can serve as potential early biomarkers for assessing the severity of GBS and cranial nerve involvement, providing significant reference value for clinical diagnosis, timely intervention, and early prevention. This evidence concerns the gene APOA1 and Guillain-Barre syndrome.